11:24 AM
 | 
Jan 12, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Acceleron reports preliminary Phase II data for ACE-083 in FSHD

Acceleron Pharma Inc. (NASDAQ:XLRN) reported preliminary data from Part 1 of a Phase II trial evaluating ACE-083 to treat facioscapulohumeral muscular dystrophy (FSHD). The company expects to start Part 2 of the trial next quarter and present additional Part 1 data this year.

The open-label first part of the trial is evaluating 150, 200 and up to 250 mg intramuscular ACE-083 every three weeks in...

Read the full 305 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >